PLI PLUS Title Details

New feature: Customize your PLUS research experience with . Learn more.

Create Account
Training Center
Contact Us

Questions? Comments?
Contact us.

Email: PLUS@pli.edu
Phone: 877.900.5291
PLI.edu
SIGN IN

Developments in Pharmaceutical and Biotech Patent Law 2015

Chair(s): David K. Barr, Daniel L. Reisner
Practice Area: Intellectual Property
Published: Oct 2015 i Other versions can be found in the Related Items tab.
ISBN: 9781402425271
PLI Item #: 136819
CHB Spine #: G1240

This version is not current.
Click here for the most recent version.

Email
Print
Add To Bookshelf
Permalink

Table of Contents
Related Items

Select All

Front Matter
Faculty Bios
Table of Contents
Chapter 1. Indefiniteness and Claim Construction: Nautilus and Teva
Chapter 2. Chapter 5 Patentability excerpt: Indefiniteness and the Requirement to Claim the Invention, Reprinted from the PLI Legal Treatise, Pharmaceutical and Biotech Patent Law (Order #15140)
Chapter 3. Chapter 9 Claim Construction, Reprinted from the PLI Legal Treatise, Pharmaceutical and Biotech Patent Law (Order #15140)
Chapter 4. Chapter 14 Biologic and Biosimilar Drug Products, Prepublication Revision, PLI Legal Treatise, Pharmaceutical and Biotech Patent Law
Chapter 5. Major Judicial Decisions Impacting Pharmaceutical and Biotech Patents (July 10, 2015)
Chapter 6. Leveraging AIA’s Tools for Your Competitive Advantage: Strategic Implications of Post-Grant Challenges for Life Sciences Companies
Chapter 7. Section 101: Patentable Subject Matter in the Aftermath of Myriad and Mayo
Chapter 8. Subject Matter Conflicts and Advance Waivers in Patent Prosecution, Counseling and Litigation
Index